Emma Visit 2: 54-Year-Old Female Diagnosed with COPD, Returning for Follow-up

Title:	Emma Visit 2: 54-Year-Old Female Diagnosed with COPD, Returning for Follow-up
Topic:	Pulmonary Disease
Relevant Terms:	Chronic Obstructive Pulmonary Disease (COPD)
Primary Audience:	Primary Care Practitioners; Physician Assistants; Nurse Practitioners and any health care professionals who treat adults with COPD.
Launch Date:	02-Jul-10
Credits:	1 AMA PRA Category 1 Credit™
Expiration Date:	01-Jul-11

Learning Objectives

Upon completion of the activity, participants should be able to:

Identify issues to be assessed during a routine COPD follow-up visit
List the various causes and manifestations of poor treatment adherence in COPD
Choose appropriate treatment strategies in COPD and determine when pharmacologic treatment escalation is appropriate
Recognize when pulmonary rehabilitation is an appropriate intervention for the COPD patient
Explain appropriate ongoing interventions for smoking cessation

Faculty

Nicola Alexander Hanania, MD, MS, FCCP, FRCP(C), FACP
Associate Professor of Medicine
Pulmonary and Critical Care Medicine
Director, Asthma Clinical Research Center
Baylor College of Medicine
Houston, Texas

Nicola A. Hanania, MD, MS Nicola A. Hanania received his Bachelor of Medicine and Surgery degree and a Master of Science degree in internal medicine from the University of Jordan, Amman, Jordan. He then completed his residency in internal medicine at the University of Jordan, followed by a residency in internal medicine and a fellowship in pulmonary medicine at the University of Toronto, Toronto, Canada. Dr. Hanania's research fellowship at the Asthma Center of the Toronto Hospital was then followed by a fellowship in critical care medicine at Baylor College of Medicine in Houston, Texas. He also received a Master of Science degree in Clinical Investigations from Baylor College of Medicine. He is certified in internal medicine, pulmonary medicine and critical care medicine.

Dr. Hanania joined the faculty at Baylor College of Medicine (BCM) in Houston, Texas in 1995 as an Assistant Professor of Medicine in the Department of Medicine, Section of Pulmonary and Critical Care Medicine. He is currently Associate Professor of Medicine and Director of the Asthma Clinical Research Center at BCM. He is also Director of the Asthma Adult Clinic and Pulmonary Diagnostic services at Ben Taub General Hospital in Houston, Texas.

Dr. Hanania is a fellow of the American College of Chest Physicians, the American College of Physicians and the Royal College of Physicians and Surgeons of Canada, as well as member of many professional societies, including the American Thoracic Society and the Society of Critical Care Medicine. He has served as Chair, Council of Networks of the American College of Chest Physicians (ACCP) and is a member of the executive committee and board of regents of ACCP and the National Asthma Education Certification Board (NAECB). Dr. Hanania is the recipient of the Fulbright and Jaworski Faculty Excellence Award in Teaching and Evaluation, an Outstanding Teacher Award in the Department of Medicine, and an Attending of the Year Award in the Pulmonary and Critical Care Section at Baylor College of Medicine.

Dr. Hanania is principal investigator for the American Lung Association Asthma Clinical Research Center and Center Director for the COPD Gene study at Baylor College of Medicine. He is also principal investigator or co-investigator of several clinical trials in asthma and COPD. His research is funded by NIH, American Lung Association and industry. His research focus is on beta2-agonists and on novel therapies for asthma and COPD. He has published and edited numerous articles, book chapters, reviews and abstracts. Dr. Hanania has been an invited to lecture or chair sessions at many local, national, and international meetings.

Dr. Hanania is currently deputy editor of Respiratory Medicine and associate editor of Therapeutic Advances in Respiratory Medicine (TARD). In addition, he is an ad-hoc reviewer for several other journals including European Respiratory Medicine, Chest, Drugs, Pulmonary Pharmacology and Therapeutics and the American Journal of Respiratory Critical Care Medicine.

Amir Sharafkhaneh, MD, PhD
Associate Professor of Medicine
Pulmonary and Critical Care Medicine
Director, Sleep Fellowship Program
Baylor College of Medicine
Director, Sleep Center at the MEDVAMC
Principal Investigator, VA Medical Center
Houston, Texas

Barbara P. Yawn, MD, MSc, FAAFP
Director of Research
Olmsted Medical Center
Adjunct Professor
Family and Community Health
University of Minnesota Medical School
Rochester, Minnesota

Sandra G. Adams, MD
Associate Professor of Medicine
Pulmonary Disease
The University of Texas Health Science Center
San Antonio, Texas

Needs
Continued progress in the basic and clinical sciences, therapeutics, technology, and surgery is leading to increased understanding and improved diagnosis and management of COPD. The purpose of this course is to update practicing primary care clinicians on the guidelines for care and the clinically relevant advances in pulmonology and to provide useful, evidence-based information on the diagnosis and treatment of chronic obstructive pulmonary disease.

Target Audience
This course is designed for the practicing primary care physicians, PAs and NPs.

Educational Methods
Case presentation, peer consultations, and learning management system.

Evaluation
Evaluation by questionnaire will address program content, presentation, and possible bias.

Accreditation/Credit Designation
Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Baylor College of Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Term of Approval
July 2010 through July 2011. Original release date: July 2010

Peer Review
In March 2010, this continuing medical education activity was reviewed by Sandra G. Adams, MD, Associate Professor of Medicine, Pulmonary/Critical Care Division, The University of Texas Health Science Center, University Health System and South Texas Veterans Health Care System, San Antonio, Texas. In order to ensure the continued scientific relevance of this enduring material, it is reviewed annually.

Dr. Adams discloses that she has received grants for Non-public Support of Research: Bayer Pharmaceuticals Corp, Boehringer Ingelheim Pharmaceuticals, Inc, Centocor, Inc, GlaxoSmithKline, Novartis Pharmaceuticals AG, Pfizer, Inc, Schering-Plough Corp; Honorarium Recipient (none were promotional; all honorarium payments were from educational grants for CME): AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corp, Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Novartis Pharmaceuticals AG, Pfizer, Inc, Schering-Plough Corp.

Program Director
Nicola A. Hanania, MD, MS, FCCP, FRCP(C), FACP
Activity Director and Contributor
Associate Professor of Medicine
Pulmonary and Critical Care Medicine
Director, Asthma Clinical Research Center
Baylor College of Medicine
Houston, Texas

Dr. Hanania discloses that he has received grants for Research Support: GlaxoSmithKline, AstraZeneca Pharmaceuticals, Novartis Pharmaceuticals, Boehringer Ingelheim, Pharmaceuticals, Inc, Dey Pharmaceuticals; Speakers Bureau: GlaxoSmithKline, AstraZeneca Pharmaceuticals; Advisory Committee: Boehringer Ingelheim Pharmaceuticals, NycoMed; Consultant: GlaxoSmithKline, Novartis Pharmaceuticals; Honorarium Recipient: GlaxoSmithKline, Novartis Pharmaceuticals, AstraZeneca Pharmaceuticals.

Amir S. Sharafkhaneh, MD, PhD
Contributor/Consultant
Amir Sharafkhaneh, MD, PhD
Associate Professor of Medicine
Pulmonary and Critical Care Medicine
Director, Sleep Fellowship Program
Baylor College of Medicine
Director, Sleep Center at the MEDVAMC
Principal Investigator, VA Medical Center
Houston, Texas

Dr. Sharafkhaneh discloses that he is a Speakers Bureau Member: GlaxoSmithKline; Boehringer Ingelheim Pharmaceuticals, Dey Pharmaceuticals; Advisory Board Member: GlaxoSmithKline, Pfizer, Inc, Dey Pharmaceuticals.

Barbara P. Yawn, MD, MSc, FAAFP
Contributor/Consultant
Director of Research
Olmsted Medical Center
Adjunct Professor
Family and Community Health
University of Minnesota Medical School
Rochester, Minnesota

Dr. Yawn discloses that she has received grants for Non-public Support of Research: GlaxoSmithKline, Novartis Pharmaceuticals; Advisory Committee: Boehringer Ingelheim-Pfizer, Forest Pharmaceuticals; Consultant: GlaxoSmithKline, Boehringer Ingelheim-Pfizer, Forest Pharmaceuticals; Honorarium Recipient: Forest Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim-Pfizer.

Notices
In order to meet the requirements of the Accreditation Council for Continuing Medical Education, it is the policy of Baylor College of Medicine that all individuals who are in a position to control the content of the CME activity (activity director, planning committee members, and faculty) disclose relevant financial relationships with commercial interests. All identified conflicts of interest are managed to help ensure that the educational material is scientifically based, accurate, current and objectively presented.
Acknowledgement of Support
These CME activities are supported by an educational grant from Pfizer, Inc., and Talecris Biotherapeutics.

Sponsored by Baylor College of Medicine, and produced in collaboration with DKBmed, LLC and RealCME, Inc.

Enter this activity!

These activities require registration. Registration time is less than two minutes, and will provide you access to your personal CMECompanion toolset.

If you are already registered, please log in.

(+) What is CMECompanion?